Dewpoint Therapeutics, Boston, MA, USA.
Dewpoint Therapeutics, Dresden, Germany.
Nat Rev Drug Discov. 2022 Nov;21(11):841-862. doi: 10.1038/s41573-022-00505-4. Epub 2022 Aug 16.
In the past decade, membraneless assemblies known as biomolecular condensates have been reported to play key roles in many cellular functions by compartmentalizing specific proteins and nucleic acids in subcellular environments with distinct properties. Furthermore, growing evidence supports the view that biomolecular condensates often form by phase separation, in which a single-phase system demixes into a two-phase system consisting of a condensed phase and a dilute phase of particular biomolecules. Emerging understanding of condensate function in normal and aberrant cellular states, and of the mechanisms of condensate formation, is providing new insights into human disease and revealing novel therapeutic opportunities. In this Perspective, we propose that such insights could enable a previously unexplored drug discovery approach based on identifying condensate-modifying therapeutics (c-mods), and we discuss the strategies, techniques and challenges involved.
在过去的十年中,人们发现无膜组件(称为生物分子凝聚物)通过在具有不同性质的亚细胞环境中分隔特定的蛋白质和核酸,在许多细胞功能中发挥关键作用。此外,越来越多的证据支持这样一种观点,即生物分子凝聚物通常通过相分离形成,其中单相系统分为由凝聚相和特定生物分子的稀释相组成的两相系统。对凝聚物在正常和异常细胞状态下的功能以及凝聚物形成机制的理解的不断深入,为人类疾病提供了新的见解,并揭示了新的治疗机会。在本观点中,我们提出,这些见解可以为基于识别凝聚物修饰治疗剂(c-mods)的以前未探索的药物发现方法提供依据,并讨论了所涉及的策略、技术和挑战。